Cohance Lifesciences Q1 Results: Consolidated Net Loss Narrows to 241M Rupees
Cohance Lifesciences reported a Q1 consolidated net loss of 241M rupees, narrowing from 489M rupees year-on-year, as revenue declined to 4.22B rupees from 5.5B rupees. Consolidated EBITDA fell sharply to 21M rupees with a 0.5% margin versus 20.4% in the prior year, while standalone net profit dropped 97.3% to ₹14 crore. The company holds consolidated net cash of approximately ₹2,512 million, supporting ongoing capital expenditure and strategic initiatives in nucleic acids and agrochemicals.
*this image is generated using AI for illustrative purposes only.
Cohance Lifesciences Limited reported a consolidated net loss of 241M rupees in Q1, narrowing from a net loss of 489M rupees in the corresponding period of the previous year. Revenue from operations declined to 4.22B rupees from 5.5B rupees year-on-year, reflecting continued pressure from shipment phasing in the Pharma Contract Development and Manufacturing Organization (CDMO) segment and a softer contribution from the CDMO business, which accounted for only 38% of revenue compared to higher levels in the prior year. The Board of Directors approved the unaudited financial results on August 5, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Walker Chandiok & Co LLP issued an unmodified limited review report on the financial statements.
On a standalone basis, net profit fell 97.3% year-on-year to ₹14 crore, while standalone revenue from operations declined 25.6% to ₹359.89 crore. Gross margins on a consolidated basis contracted to 71.5% from 73.0% in the corresponding quarter of the previous year, largely due to product mix shifts and higher freight and logistics costs.
Financial Performance Highlights
The consolidated EBITDA stood at 21M rupees, representing a margin of 0.5%, compared to 1.12B rupees and a margin of 20.4% in the prior year period. The standalone adjusted EBITDA was ₹332 million, representing a margin of 9.2%, down from ₹1,263 million (26.1%) in Q1FY26, reflecting negative operating leverage and the impact of lower revenue volumes. The consolidated result included an EBITDA loss of ₹328 million from NJ Bio, a subsidiary that contributed to the wider bottom-line decline.
The following table summarises the key financial metrics for the quarter:
| Metric | Standalone Q1FY27 | Standalone Q1FY26 | YoY Change | Consolidated Q1FY27 | Consolidated Q1FY26 | YoY Change |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹359.89 crore | ₹483.58 crore | -25.6% | 4.22B rupees | 5.5B rupees | NM |
| Net Profit / (Loss) | ₹14 crore | ₹52.57 crore | -97.3% | (241M rupees) | (489M rupees) | NM |
| Adjusted EBITDA | ₹332 million | ₹1,263 million | -73.7% | 21M rupees | 1.12B rupees | NM |
| EBITDA Margin (%) | 9.2% | 26.1% | -16.9 pts | 0.5% | 20.4% | -19.9 pts |
Strategic Initiatives and Segment Updates
Management highlighted two immediate strategic priorities: building an integrated nucleic-acid business through Sapala Organics Private Limited and repositioning the Agrochemicals segment towards an innovator-product-led portfolio. The Board also approved reorganization measures at Sapala, including amendment agreements with selling shareholders to unify the operating model for the nucleic acid business.
In the Pharma CDMO segment, two recently commercialized molecules are scheduled for delivery in Q2 and Q3 FY27. A significant restocking order for a commercial molecule affected by inventory destocking in FY26 has been secured, providing delivery visibility for Q4 FY27 and FY28. The API+ segment remained resilient despite a 10.4% year-on-year revenue decline, supported by favorable pricing and product mix. Specialty Chemicals revenue declined 34.7% year-on-year, primarily due to expected second-half-weighted phasing in Agrochemicals.
Liquidity and Capital Position
The divergence between standalone and consolidated performance underscores the transitional challenges following recent acquisitions. While the core standalone business maintained a positive adjusted EBITDA margin of 9.2%, the consolidated entity absorbed significant losses from subsidiaries, including NJ Bio, which reported an EBITDA loss of ₹328 million. The company maintains a strong liquidity position with consolidated net cash of approximately ₹2,512 million as of June 30, 2026, supporting its capital expenditure plans of ₹598 million during the quarter.
Historical Stock Returns for Cohance Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.07% | +0.87% | -5.19% | +17.10% | -55.20% | -19.33% |
How will the integration of Sapala Organics impact Cohance's nucleic acid business margins and revenue contribution in the next two fiscal years?
What specific operational measures is management implementing to reverse the negative operating leverage and improve the consolidated EBITDA margin from its current 0.5%?
Given the significant EBITDA loss from NJ Bio, what is the strategic roadmap for turning this subsidiary profitable or mitigating its drag on consolidated results?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
